HomeBest options strategy › BDTX

Best Options Strategy for BDTX

Di Dennis Bosmans · Aggiornato 2026-07-22 · 2 min di lettura · Avvertenza sui rischi

Looking for the best options strategy for Black Diamond Therapeutics, Inc. (BDTX)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live BDTX option chain right now, and a simple map from your view on BDTX to the strategy that fits it. Model any of them in the calculator before you trade.

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics is a clinical-stage oncology company developing targeted therapies designed for tumors driven by specific genetic mutations. The company's pipeline centers on its MasterKey inhibitor platform, which aims to address hard-to-treat cancers with precision. Silevertinib, its most advanced candidate, crosses the blood-brain barrier and targets mutated EGFR; it is being tested in Phase 2 trials for EGFR-mutant lung cancer and glioblastoma. The company is also advancing BDTX-4933, a brain-penetrant RAF inhibitor in Phase 1 testing for solid tumors carrying KRAS, NRAS, or BRAF mutations. Additionally, BDTX-4876, which selectively targets oncogenic FGFR2 and FGFR3 mutations, remains in preclinical development.

Black Diamond generates value by advancing these drug candidates through the clinical trial process, with the ultimate goal of commercializing approved therapies. The company operates in the oncology market, which encompasses treatment options for genetically defined cancer subtypes. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond was previously known as ASET Therapeutics before rebranding in January 2018. As a clinical-stage…

Today's top-scoring strategy for BDTX

Our engine ranks defined-risk strategies on the live BDTX chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.

Iron Butterfly neutral
Price: $1.82Implied volatility: 214%Expiration: 2026-08-21 (29d)
ActionQtyTypeStrikePremium
BuyPUT$1.5$0.05
SellPUT$1.5$0.05
SellCALL$1.5$0.55
BuyCALL$2.5$0.05
P/L at expiry vs today At expiry Today ±1σ
$1$2$3
Profitto massimo
$50
Perdita massima
−$50
Credito netto (incassato)
$50
Punto/i di pareggio
$2.00
Position Greeks
Δ
−32.09
Γ
5.568
Θ
−0.12
ν
0.03
Time decay (price held)

Simulazione

Simulazione prospettica di 6,000 traiettorie di prezzo lognormali fino alla scadenza — non è un backtest storico.

Percentuale di successo
66%
P/L medio
$16
Mediana
$47
Mov. atteso (1σ)
60%
5° pct
−$50
25° pct
−$30
75° pct
$50
95° pct
$50

Analisi della strategia

Traiettorie di prezzo simulate (tempo × prezzo)
now $2BE $2$1$2$40d15d29d
$-49$0$49

Greche vs prezzo

Δ — P/L in $ per ogni movimento di $1 del sottostante (esposizione equivalente in azioni).
Θ — P/L in $ al giorno dal decadimento temporale.
ν — P/L in $ per ogni +1% di volatilità implicita.
Γ — quanto velocemente cambia il delta per ogni movimento di $1.

Prezzo × volatilità (oggi)

−30%−15%IV+15%+30%
$2−$5−$1$3$6$8
$2−$1$2$5$8$10
$2$3$6$8$10$12
$2$7$9$11$13$14
$2$11$12$14$15$17
$2$15$16$16$18$19
$2$19$19$19$20$21
$2$23$22$22$23$23
$2$27$26$25$25$26
$1$31$29$28$28$28
$1$35$33$31$31$30
Analyze BDTX in the calculator → Share this pick ↗

Live scan from 2026-07-22 · quotes delayed ~15 minutes

Backtest storico: come si sarebbe comportata una Iron Butterfly su BDTX

Abbiamo simulato in modo approssimativo una Iron Butterfly su BDTX che avresti aperto ripetutamente nell'ultimo anno (93 ingressi storici, ciascuno mantenuto fino alla scadenza), con i premi d'ingresso modellati tramite Black-Scholes. Ecco come sarebbe andata sulla reale storia dei prezzi di BDTX — un backtest didattico, non una previsione dei rendimenti futuri.

Trade
93
Percentuale di successo
11%
P/L totale
-$819
Rendimento medio sul rischio
-22%
Trade migliore
$111
Trade peggiore
-$166
P/L cumulativo lungo il backtest

In via approssimativa: i premi d'ingresso sono modellati con Black-Scholes sulla base della volatilità realizzata trailing, mantenuti fino alla scadenza e regolati contro il reale prezzo di chiusura storico. Fill reali, volatilità implicita e slippage differiscono — consideralo come contesto indicativo, non come rendimento esatto.

Implied volatility

BDTX is currently trading with high implied volatility, which makes its options expensive — and attractive to sell. On the options we scanned that was around 214% implied volatility, and higher implied volatility means richer premiums and wider expected moves.

Options on BDTX currently price in about 214% implied volatility, versus roughly 72% the stock has actually realised over the past month. That makes options relatively expensive — an edge for strategies that sell premium, such as credit spreads and iron condors.

Off that volatility, the options market is pricing a move of about ±$1,1 (±60%) in BDTX by 2026-08-21 — a range of roughly $0,72 to $2,93. Strikes inside that band hold most of the premium and see most of the action.

In evidenza dalla option chain di BDTX: open interest, volume e skew

La option chain live di BDTX mostra un rapporto put/call sull'open interest di 0.03 (bullish-leaning (more calls)), con una volatilità implicita at-the-money intorno al 155.1%. L'open interest si concentra sulla call a 2.5 — un classico "muro" di resistenza — e sulla put a 1.5, un "muro" di supporto: esattamente gli strike a cui gli scrittori di opzioni sono più esposti verso la scadenza.

Put/Call OI
0.03
Volume Put/Call
0.06
ATM IV
155.1%
Skew IV put–call
-74.2
Muro OI call
$3 · 99
Muro OI put
$2 · 6
Call più attiva
$2 · 30
Put più attiva
$2 · 2

Istantanea di open interest, volume e volatilità implicita per la scadenza scansionata più vicina — contesto, non un segnale di trading.

Earnings & IV crush

BDTX's next earnings report is due around 6 agosto 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.

With earnings roughly 15 days out, BDTX's 214% implied volatility is inflated by event premium — and it usually collapses the moment results drop ("IV crush"). That rewards defined-risk premium sellers when the move stays muted, and punishes option buyers who paid the inflated price. Keep size small and risk defined through the report.

Key figures

Market cap
$105M
Beta (vs market)
3.25
52-week range
$1.60–$4.94 (7% up the range)
Short interest
11.3% of float · 2.3 days to cover

With 11.3% of BDTX's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.

How to choose an options strategy for BDTX

Start with your outlook on BDTX, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:

Bullish

You expect BDTX to rise

Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.

Long Call → Bull Call Spread →

Bearish

You expect BDTX to fall

Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.

Long Put → Bear Put Spread →

Neutral

You expect BDTX to trade in a range

Sell an iron condor to collect premium while BDTX stays between two strikes, or write a covered call against shares you already own.

Iron Condor → Covered Call →

⧉ Embed this free calculator on your site →

How we pick the best strategy

For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →

Open BDTX in the free calculator →

Domande frequenti

What is the best options strategy for BDTX?

It depends on your outlook. Bullish traders often use a long call or bull call spread on BDTX; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.

Are BDTX options liquid enough to trade?

Black Diamond Therapeutics, Inc. (BDTX) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.

How much money do I need to trade BDTX options?

Buying a single BDTX call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.

Is this financial advice?

No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade BDTX or any security. Do your own research.

Cosa fa Black Diamond Therapeutics, Inc.?

Black Diamond Therapeutics, Inc. (BDTX) opera nel settore Biotechnology. La sezione "Informazioni su Black Diamond Therapeutics, Inc." qui sopra offre un quadro più completo di ciò che fa l'azienda e di come genera profitti.

Black Diamond Therapeutics, Inc. paga dividendi?

Qui non mostriamo un rendimento da dividendo confermato per Black Diamond Therapeutics, Inc., quindi consideralo incerto: prima di scrivere delle call controlla il dividendo attuale e la data di stacco cedola (ex-dividend) presso il tuo broker — una data di stacco imminente può innescare un'assegnazione anticipata sulle call scritte in-the-money.

Quando Black Diamond Therapeutics, Inc. pubblica gli utili?

I prossimi utili di Black Diamond Therapeutics, Inc. sono attesi intorno al 6 agosto 2026. La volatilità implicita di solito sale in avvicinamento alla pubblicazione e crolla bruscamente dopo (IV crush) — un aspetto importante per qualsiasi posizione in opzioni che mantieni oltre quella data.

Tickers related to BDTX

Comparing BDTX with similar names can help you choose the best options strategy:

GOSSGossamer Bio, Inc.ALECAlector, Inc.STOKStoke Therapeutics, Inc.

Informazioni sull’azienda

Sede
245 First Street, 18th Floor, Cambridge, MA, 02142, United States
Settore
Biotechnology
Dipendenti
21
CEO
Dr. Mark A. Velleca M.D., Ph.D.
Telefono
617 252 0848
Sito web
www.blackdiamondtherapeutics.com

Best Options Strategy by Ticker →

Solo per uso didattico. Le quotazioni sono ritardate di circa 15 minuti e nulla di ciò che è riportato qui è consulenza finanziaria. Il trading di opzioni comporta un rischio sostanziale di perdita. Privacy · Terms.